2009 Profitable Year for Ra Medical Systems, Inc.
Carlsbad, CA – March 15, 2010 – For Immediate Release
Ra Medical Systems, Inc. announced today that it had record sales and was profitable in 2009. In addition to a significant increase in revenue over 2008, the company showed increasing gross margins.
Melissa Burstein, Vice President for Ra Medical, commented, "We want to recognize the hard work and dedication of our sales teams across the country and extend our appreciation to our customers. We are especially pleased that we were able to increase our sales force and achieve our sales goals in such a difficult year for dermatology laser companies.”
Ra Medical, now in its eight year, has lasers in more than 80% of US states and in more than a dozen countries. The company expanded its presence in academic institutions and is poised for sustainable growth in this market.
Daniel Sanchez, Senior Accountant, commented, “Ra Medical’s profits combined with its insignificant debt is helping the company continue innovation and new product launches in the near future. We are now in our 5th straight year of positive earnings.”
Stephan Beal, Vice President of Sales, added, “Our sales success at the recent American Academy of Dermatology meeting in Miami demonstrated our unique place in the market, offering affordable, state of the art, excimer lasers for medically necessary and reimbursed procedures. Existing customers commented that our PHAROS lasers are among the most heavily used and profitable pieces of equipment in their practices.”
Ra Medical Systems, Inc., a privately held medical device company was founded in 2002 to commercialize medical excimer lasers. Based in Carlsbad, CA, the company manufactures and markets excimer laser systems including the PHAROS for the treatment of skin diseases including psoriasis, vitiligo, atopic dermatitis, and leukoderma. Future development will expand upon our core technology platform to offer innovative solutions to unmet medical needs beyond dermatology.
For more information please call investor relations or sales at 760-804-1648.
This media release may contain forward-looking statements regarding, but not limited to, clinical studies and results of those studies, management, market potential, distributor success, market size, international approvals, FDA clearances, marketing, future events and performance of the company, which involve risks and uncertainties that could materially affect actual results.
|
